First real-world study of RYTELO shows safety and efficacy in lower-risk MDS patients at EHA 2026.

Geron Corporation announced that the first real-world evidence study of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the EHA 2026 Congress. Conducted at Moffitt Cancer Center, the study showed safety and efficacy consistent with prior Phase 3 trials in heavily transfusion-dependent patients, including those with prior treatments. The data supports RYTELO as a preferred treatment option for LR-MDS patients with significant transfusion burdens. Additional presentations on related clinical programs will also be featured at EHA and ASCO 2026.